#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3150	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2369	392.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1785	1785	T	533	T,G	460,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3150	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2369	392.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1519	1519	C	473	C,A	375,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5018	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3826	392.0	0	.	n	.	0	T695C	SNP	695	695	T	1139	1139	C	382	C	313	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5018	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3826	392.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1781	1781	A	436	A	351	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5018	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3826	392.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2415	2415	C	452	C,T,A	368,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5018	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3826	392.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2489	2489	A	461	A	372	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5018	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3826	392.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3041	3041	C	462	C,T	369,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	340	folP	855	855	100.0	folP.l15.c4.ctg.1	1804	56.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1183	1185	AGC	74;74;74	A;G;C	53;57;58	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	916	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3656	74.9	0	.	p	.	0	F91Y	NONSYN	271	273	TTC	735	737	TAC	64;64;64	T;A;C,A	54;54;55,1	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	916	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3656	74.9	1	SNP	p	D95G	0	.	.	283	285	GAC	747	749	GAC	66;65;65	G;A;C	54;56;54	gyrA.WHO_G_01105:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	916	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3656	74.9	1	SNP	p	D95N	0	.	.	283	285	GAC	747	749	GAC	66;65;65	G;A;C	54;56;54	gyrA.WHO_G_01105:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	334	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1641	60.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	610	612	ACC	86;86;87	A;C,A;C	67;67,1;69	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	334	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1641	60.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	808	810	CAC	103;103;103	C;A;C	83;86;87	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	334	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1641	60.7	1	SNP	p	G45D	0	.	.	133	135	GGC	628	630	GGC	89;89;89	G;G;C	71;68;67	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	222	mtrR_promoter	250	250	98.8	mtrR_promoter.l15.c17.ctg.1	1227	53.8	0	.	n	.	0	T10C	SNP	10	10	T	503	503	C	95	C,A	74,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	222	mtrR_promoter	250	250	98.8	mtrR_promoter.l15.c17.ctg.1	1227	53.8	0	.	n	.	0	G120A	SNP	120	120	G	613	613	A	89	A,T	77,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	222	mtrR_promoter	250	250	98.8	mtrR_promoter.l15.c17.ctg.1	1227	53.8	0	.	n	.	0	A197.	DEL	197	197	A	689	689	A	84	A	69	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	858	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3207	79.9	1	SNP	p	D86N	0	.	.	256	258	GAC	689	691	GAC	118;119;119	G;A,T;C	93;85,1;93	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	858	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3207	79.9	1	SNP	p	S87R	0	.	.	259	261	AGT	692	694	AGT	119;118;117	A;G;T	87;93;95	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	858	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3207	79.9	1	SNP	p	S87I	0	.	.	259	261	AGT	692	694	AGT	119;118;117	A;G;T	87;93;95	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	858	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3207	79.9	1	SNP	p	S87W	0	.	.	259	261	AGT	692	694	AGT	119;118;117	A;G;T	87;93;95	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	858	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3207	79.9	1	SNP	p	S88P	0	.	.	262	264	TCC	695	697	TCC	117;117;118	T;C;C	92;92;92	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	726	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2908	74.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1688	1690	GGC	99;99;100	G;G,T;C,T	79;80,1;78,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1430	1432	GCA	83;83;83	G;C;A	64;67;68	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1433	1435	ATC	82;81;81	A;T;C,A	68;68;65,2	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1445	1447	GTG	80;80;80	G;T;G	68;65;64	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1445	1447	GTG	80;80;80	G;T;G	68;65;64	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1949	1951	ACC	61;61;60	A;C;C	54;54;51	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2003	2005	GTG	59;59;60	G;T;G	50;43;48	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2003	2005	GTG	59;59;60	G;T;G	50;43;48	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2126	2128	GGC	65;65;65	G;G;C	51;53;55	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2135	2137	GGC	61;60;60	G;G;C	49;52;49	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2885	67.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2153	2155	TCG	61;61;61	T,G;C;G	48,1;50;52	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1028	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3426	89.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1784	1786	CCG	96;97;95	C;C;G,T	74;74;76,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	514	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2012	76.2	0	.	p	.	0	S22G	NONSYN	64	66	AGC	501	503	GGC	91;91;91	G;G;C	78;75;78	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	514	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2012	76.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	683	683	C	92	C	72	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	609	611	GAA	117;116;117	G;A;A	99;97;98	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	897	899	GAT	115;113;112	G;A;T	87;84;85	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1020	1022	TCA	109;110;109	T,G;C;A	88,1;93;96	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1149	1151	GTC	111;111;110	G;T;C	86;91;91	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1479	1481	GCA	108;108;108	G,A;C;A	90,1;93;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	0	.	p	.	0	I335N	NONSYN	1003	1005	ATC	1500	1502	AAC	106;106;105	A;A,C;C	90;88,1;91	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	1	SNP	p	G120K	1	.	.	358	360	AAG	855	857	AAG	112;112;113	A,C;A;G	87,1;91;89	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	1	SNP	p	D121N	0	.	.	361	363	GAC	858	860	GAC	113;113;113	G;A;C,A	91;90;87,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	544	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1981	80.5	1	SNP	p	A121D	1	.	.	361	363	GAC	858	860	GAC	113;113;113	G;A;C,A	91;90;87,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1744	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5327	98.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2170	2172	CAT	93;92;92	C;A;T	80;78;79	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	306	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1352	67.9	1	SNP	p	V57M	1	.	.	169	171	ATG	703	705	ATG	136;136;136	A;T;G	110;105;107	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
